课题基金 / 基金详情

DNA Cages as a Platform for Efficient and Selective Delivery of Therapeutics into Tumor Cells

DNA Cages as a Platform for Efficient and Selective Delivery of Therapeutics into Tumor Cells
DNA 笼作为有效、选择性地将治疗药物递送至肿瘤细胞的平台
批准号：
270238
负责人：
Sleiman Hanadi
金额：
$29.14万
依托单位：
Lady Davis Institute for Medical Research (Mtl)
依托单位国家：
加拿大
项目类别：
Operating Grants
财政年份：
2012
资助国家：
加拿大
项目状态：
已结题
起止时间：
2012-10-01 至 2015-10-01
来源：
https://webapps.cihr-irsc.gc.ca/decisions/p/project_details.html?applId=270238&lang=en
关键词：
Anti-Apoptotic Protein Bcl-2 Antisense Oligonucleotides Chronic Lymphocytic Leukemia Dna Cages And Nanotubes Drug Resistant Tumors Enzyme-Mediated Repair Of Dna Damage Nucleic Acid Delivery Oligonucleotide Analogues Sirna Targeted Cancer Therapy

项目摘要

项目成果

Sleiman Hanadi的其他基金

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
General drug cytotoxicity and drug resistance are major hurdles in traditional cancer therapies, stemming from the nonspecific delivery of cancer therapeutics to normal and cancerous cells simultaneously. We aim to develop a new method for targeted cancer
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Targeting atypical B7 family checkpoints in poor-outcome triple-negative breast cancers
  • 批准号：
    490501
  • 项目类别：
    Operating Grants
  • 资助金额：
    $76.63万
  • 财政年份：
    2023
  • 负责人：
    Sleiman Hanadi
  • 依托单位：
    McGill University
海外基金